Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma

Inclusion criteria

• Age ≥18 years with stage I-IV indolent NHL*
• Able to provide informed consent
• Histologically confirmed indolent NHL involving one or both orbits. If bilateral, biopsy of only one orbit is permitted as long as high clinical suspicion of contralateral orbit involvement
• Measurable orbital disease after biopsy, either clinically or radiographically
• ECOG performance status 0-3
• Life expectancy >12 months
• Available for treatment and follow-up (including scheduled post-treatment imaging and ophthalmologic exam)
• Able and willing to complete quality of life questionnaires via paper or online portal if they provide their email address on the informed consent document

• Stage II-IV allowed but if systemic therapy given after RT the timing will be recorded, and subjects will be stratified according to receipt of systemic therapy

Exclusion criteria

• Aggressive NHL histology (including grade 3B follicular lymphoma)
• Prior RT to orbit
• Patients requiring treatments outside standard clinical hours
• Systemic therapy for lymphoma is not permitted within the period of time between 2 weeks prior to RT start and 2 weeks after RT completion
• Patients who are pregnant
• History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death and/or treated with expected curative outcome (for example, appropriately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, localized prostate cancer, breast ductal carcinoma in-situ, or stage I endometrial cancer)
• Any medical condition that, in the investigator's judgement, would preclude the individual's safe participation in and completion of the study, or could affect interpretation of the results (e.g. pre-existing retinopathy, active connective tissue disease)
• Inability to comply with study and follow-up procedures